Baylor Breast Care Center
16
1
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
50.0%
8 terminated/withdrawn out of 16 trials
38.5%
-48.0% vs industry average
6%
1 trials in Phase 3/4
140%
7 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
Role: lead
Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer
Role: lead
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Role: lead
Neoadjuvant GW572016 to Treat Breast Cancer
Role: lead
Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer
Role: lead
Lapatinib and Trastuzumab With or Without Endocrine Therapy
Role: lead
Nexium Study To Suppress Nausea During Chemotherapy
Role: lead
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
Role: lead
Brain Mets - Capecitabine Plus Sunitinib and WBRT
Role: lead
Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer
Role: lead
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer
Role: lead
Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer
Role: lead
Bexarotene in Preventing Breast Cancer in Women at Genetic Risk
Role: lead
Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients
Role: lead
Biologic Correlative Taxotere/AC
Role: lead
Neoadjuvant Taxotere
Role: lead
All 16 trials loaded